Vemurafenib launch date

Vemurafenib (Vemurafenib) is a competitive kinase inhibitor that is active against mutated BRAF kinases such as V600E. It exerts its function by binding to the ATP-binding domain of mutant BRAF. Vemurafenib was approved by the U.S. Food and Drug Administration (FDA) in August 2011 for the treatment of advanced melanoma, making it the first drug to gain regulatory approval through fragment-based lead compound discovery under the trade name Zelboraf. Vemurafenib was approved for use in Canada in February 2012.

In February 2012, the European Medicines Agency (EMA) approved vemurafenib as monotherapy for the treatment of adults with BRAF V600E mutation-positive unresectable or metastatic melanoma, the most aggressive form of skin cancer. They believe that vemurafenib has been convincingly shown to improve overall survival and delay the progression of "BRAF V600-positive" melanoma, which has spread or cannot be removed with surgery. In November 2017, the FDA approved vemurafenib for the treatment of patients with Erdheim-Chester disease (ECD), a rare histiocytic tumor.

Vemurafenib The original drug was approved by the State Food and Drug Administration in 2017 and was launched in China under the trade name Zobovo. It subsequently entered the scope of medical insurance. The price of each box of 240mg*56 tablets may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.